tag:blogger.com,1999:blog-4908756863334307252.post7468055885858747170..comments2024-01-08T14:02:59.211-08:00Comments on Brain Today: Can a Brain Scan Predict Alzheimer's?Dennis Fortierhttp://www.blogger.com/profile/04495517779435972130noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-4908756863334307252.post-42028399190325532452011-04-13T14:59:12.454-07:002011-04-13T14:59:12.454-07:00I'm glad to have found your blog and read this...I'm glad to have found your blog and read this post. The media sees itself as a watchdog, but when it comes to health, it desperately needs its own watchdogs. As a freelance writer who specializes in health and senior issues, I'm a member of said media. I look forward to more posts so I can continue striving to watchdog my own self. :-)Leigh Annhttp://www.lawordsmith.comnoreply@blogger.comtag:blogger.com,1999:blog-4908756863334307252.post-63169885126031739612011-04-06T12:18:52.746-07:002011-04-06T12:18:52.746-07:00Thanks for this comment. I wrote about the spinal...Thanks for this comment. I wrote about the spinal fluid research earlier (you can search this blog for "spinal fluid" and find several entries). You can see the same confusion between "predicting" and "identifying" in that coverage as well.Dennis Fortierhttps://www.blogger.com/profile/04495517779435972130noreply@blogger.comtag:blogger.com,1999:blog-4908756863334307252.post-91645025609326190382011-04-06T12:00:38.143-07:002011-04-06T12:00:38.143-07:00Brain Scan and spinal fluid test... here is a spin...Brain Scan and spinal fluid test... here is a spinal tap that's close to completion<br /><br /> The American Business Journal: Amorfix Life Sciences: 01 April, 2011 02:52:00<br /> Mississauga, Ontario-based Amorfix Life Sciences has announced that is developing a new diagnostic test that is able to measure clumped protein fragments, called aggregated beta amyloid, in human cerebral spinal fluid which may indicate the presence of Alzheimer’s disease, making it easier to accurately diagnose.<br />Amorfix Life Sciences is a product development company focused on diagnostics and therapeutics for misfolded protein diseases including Alzheimer’s disease, cancers and ALS. The company is forging new ground in the ability to develop diagnostics using unique regions, or Disease Specific Epitopes, which, once identified, can be targeted in the pursuit of treatment and therapeutics.<br />Currently, the only definitive diagnosis for Alzheimer’s is a post-mortem examination of brain tissue.The Amorfix test is conducted on the cerebral spinal fluid from living patients, representing a significant step forward in early detection and subsequent treatment of the disease. “ The breakthrough was we measure levels of aggregated beta amyloid on the cerebral spinal fluid on patients who were diagnosed with Alzheimer’s and compared those levels to levels from aged matched control subjects who did not have Alzheimer’s disease and found that there was a difference “ , says Dr. Robert Gundel, Amorfix President and CEO. <br />“ The importance of our work and its real significant is the measurement of the aggregated beta amyloid, which leads to plaque formation in the brain” says Gundel. Our hope is to one day be able to use this test on patients showing early signs of dementia in order to predict which patients may progress rapidly into the disease and which may not.”Anonymousnoreply@blogger.com